Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*
Mark Tidswell(Tufts University), Steven M. Opal(Brown University), Melvyn Lynn(Memorial Hospital of Rhode Island), Jagadish Gogate(Memorial Hospital of Rhode Island), Steven P. LaRosa(Eli Lilly (United States)), William Tillis(Eisai (Japan)), Janice L. Wheeler(Memorial Hospital of Rhode Island), Alec E. Wittek(Eisai (Japan)), Richard Kao(Eisai (Japan))
Cited by 226
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k